Literature DB >> 18622263

Genetic polymorphisms in the 5'-flanking region of human UDP-glucuronosyltransferase 2B7 affect the Nrf2-dependent transcriptional regulation.

Akiko Nakamura1, Miki Nakajima, Eriko Higashi, Hiroyuki Yamanaka, Tsuyoshi Yokoi.   

Abstract

OBJECTIVES: Human uridine diphosphate-glucuronosyltransferase 2B7 (UGT2B7) plays important roles in the metabolism of some clinical drugs, carcinogens, and steroid hormones. The molecular mechanisms of the inducible expression of UGT2B7 in response to xenobiotics have not been fully clarified. We sought to investigate whether the UGT2B7 is under the control of NF-E2 p45-related factor 2 (Nrf2), a key transcriptional factor regulating the expression of cytoprotective enzymes.
METHODS: HepG2, HuH7, HLE, and Caco-2 cells were treated with sulforaphane (SFN), and the UGT2B7 mRNA levels were determined by real-time reverse transcriptase PCR. These cells were genotyped for the UGT2B7*2 (H268Y) allele using the PCR-restriction fragment length polymorphism method. Luciferase analyses and gel shift analyses were performed to identify the responsive regions for Nrf2 signaling.
RESULTS: The UGT2B7 mRNA was induced by SFN in HepG2 and HuH7 genotyped as UGT2B7*1/*1, but not in HLE and Caco-2 cells genotyped as UGT2B7*2/*2. In HepG2 cells, the UGT2B7 protein level and morphine glucuronosyltransferase activity were also significantly induced by SFN. The induction was prominently decreased with small interfering RNA for Nrf2. In the 5'-flanking region (-2.5 kb) of the UGT2B7*2 allele, a 324-base pair insertion at -2067 and 12 single nucleotide polymorphisms simultaneously existed. Luciferase analyses and gel shift analyses revealed that an antioxidant responsive element at -1170 was responsible for the transactivation by Nrf2. In addition, a region from -990 to -858 on the UGT2B7*1 allele was also responsible for the transactivation by Nrf2. Abrogation of the Nrf2-dependent transactivation of the UGT2B7*2 allele was owing to the single nucleotide polymorphism -900A>G.
CONCLUSION: UGT2B7 is transcriptionally regulated by Nrf2, but the mechanism is hindered by polymorphisms in the promoter region of UGT2B7*2. The allele-specific mechanism may cause variability of the glucuronidation in response to oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18622263     DOI: 10.1097/FPC.0b013e32830500c9

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  7 in total

1.  Allelic imbalance (AI) identifies novel tissue-specific cis-regulatory variation for human UGT2B15.

Authors:  Chang Sun; Catherine Southard; David B Witonsky; Olufunmilayo I Olopade; Anna Di Rienzo
Journal:  Hum Mutat       Date:  2010-01       Impact factor: 4.878

2.  UGT2B gene expression analysis in multiple tobacco carcinogen-targeted tissues.

Authors:  Nathan R Jones; Philip Lazarus
Journal:  Drug Metab Dispos       Date:  2014-01-23       Impact factor: 3.922

3.  The use of allelic imbalance to ascertain cis-regulation for human UGT2B7 in vivo.

Authors:  Pin-Yi Wang; Dezheng Huo; Chang Sun; Olufunmilayo I Olopade
Journal:  Eur J Clin Pharmacol       Date:  2013-06-06       Impact factor: 2.953

4.  Lack of association between common UGT2B nonsynonymous single-nucleotide polymorphisms and breast cancer in populations of African ancestry.

Authors:  Chang Sun; Dezheng Huo; Barbara Nemesure; Anselm Hennis; M Cristina Leske; Suh-Yuh Wu; Qun Niu; Olufunmilayo I Olopade; Anna Di Rienzo
Journal:  Int J Cancer       Date:  2011-08-24       Impact factor: 7.396

5.  Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients.

Authors:  Natalia Sutiman; Joanne Siok Liu Lim; Thomas E Muerdter; Onkar Singh; Yin Bun Cheung; Raymond Chee Hui Ng; Yoon Sim Yap; Nan Soon Wong; Peter Cher Siang Ang; Rebecca Dent; Werner Schroth; Matthias Schwab; Chiea Chuen Khor; Balram Chowbay
Journal:  Clin Pharmacokinet       Date:  2016-10       Impact factor: 6.447

Review 6.  Modulating NRF2 in Disease: Timing Is Everything.

Authors:  Matthew Dodson; Montserrat Rojo de la Vega; Aram B Cholanians; Cody J Schmidlin; Eli Chapman; Donna D Zhang
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-09-26       Impact factor: 13.820

Review 7.  Genetic Variations on Redox Control in Cardiometabolic Diseases: The Role of Nrf2.

Authors:  Cecilia Zazueta; Alexis Paulina Jimenez-Uribe; José Pedraza-Chaverri; Mabel Buelna-Chontal
Journal:  Antioxidants (Basel)       Date:  2022-03-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.